Literature DB >> 20923622

Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder.

Robert M Post1, Lori L Altshuler, Mark A Frye, Trisha Suppes, Paul E Keck, Susan L McElroy, Gabriele S Leverich, David A Luckenbaugh, Michael Rowe, Scott Pizzarello, Ralph W Kupka, Heinz Grunze, Willem A Nolen.   

Abstract

OBJECTIVE: To evaluate the clinical correlates of and types of naturalistic treatments associated with sustained improvement/remission for at least 6 months in outpatients with bipolar disorder.
METHOD: Five hundred twenty-five outpatients with bipolar disorder (77.7% bipolar I) gave informed consent, had their mood rated daily on the National Institute of Mental Health Life Chart Method for a minimum of at least 1 year, and recorded all medications. Demographics and clinical characteristics of patients with a "sustained response" (ratings of "improved" or "very much improved" on the Clinical Global Impressions-Bipolar Version for a period of at least 6 months) versus nonresponders were compared. The study was conducted from 1996 to 2002.
RESULTS: Of the 429 patients who were ill at study entry, 195 (45.5%) showed a sustained response; 54.5% showed no or insufficient response. A mean of 2.98 medications was given at time of improvement, which occurred after a mean of 18 months of participation in the study. Lithium and valproate were the medications most frequently prescribed at the time of improvement and had among the highest overall success rates. Equally complex regimens were employed in the nonresponders who, however, had a more adverse clinical course prior to network entry. Nonresponders were ultimately exposed to more antidepressants and antipsychotics than the sustained responders.
CONCLUSIONS: A mean of 1.5 years and at times highly complex medication regimens were required to achieve a sustained response for 6 months during naturalistic outpatient treatment of bipolar disorder. Delineating the clinical and biologic correlates of individual response to combination treatment is a very high clinical research priority, as is developing new treatment strategies for the large proportion of patients who fail to respond in a sustained fashion. © Copyright 2010 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20923622     DOI: 10.4088/JCP.08m04811yel

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  26 in total

1.  Illness progression as a function of independent and accumulating poor prognosis factors in outpatients with bipolar disorder in the United States.

Authors:  Robert M Post; Lori L Altshuler; Gabriele S Leverich; Willem A Nolen; Ralph Kupka; Heinz Grunze; Mark A Frye; Trisha Suppes; Susan L McElroy; Paul E Keck; Mike Rowe
Journal:  Prim Care Companion CNS Disord       Date:  2014-12-18

2.  White Matter Microstructure in Bipolar Disorder Is Influenced by the Interaction between a Glutamate Transporter EAAT1 Gene Variant and Early Stress.

Authors:  Sara Poletti; Irene Bollettini; Cristina Lorenzi; Alice Vitali; Silvia Brioschi; Alessandro Serretti; Cristina Colombo; Francesco Benedetti
Journal:  Mol Neurobiol       Date:  2018-05-22       Impact factor: 5.590

3.  More assortative mating in US compared to European parents and spouses of patients with bipolar disorder: implications for psychiatric illness in the offspring.

Authors:  Robert M Post; Lori L Altshuler; Ralph Kupka; Susan L McElroy; Mark A Frye; Michael Rowe; Heinz Grunze; Trisha Suppes; Paul E Keck; Willem A Nolen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-08-11       Impact factor: 5.270

4.  Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder.

Authors:  Francesco Benedetti; Sara Poletti; Daniele Radaelli; Clara Locatelli; Adele Pirovano; Cristina Lorenzi; Benedetta Vai; Irene Bollettini; Andrea Falini; Enrico Smeraldi; Cristina Colombo
Journal:  Psychopharmacology (Berl)       Date:  2014-10-28       Impact factor: 4.530

5.  Influence of an interaction between lithium salts and a functional polymorphism in SLC1A2 on the history of illness in bipolar disorder.

Authors:  Sara Dallaspezia; Sara Poletti; Cristina Lorenzi; Adele Pirovano; Cristina Colombo; Francesco Benedetti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

6.  Prenatal antiepileptic exposure associates with neonatal DNA methylation differences.

Authors:  Alicia K Smith; Karen N Conneely; D Jeffrey Newport; Varun Kilaru; James W Schroeder; Page B Pennell; Bettina T Knight; Joseph C Cubells; Zachary N Stowe; Patricia A Brennan
Journal:  Epigenetics       Date:  2012-05-01       Impact factor: 4.528

7.  Comparing medication attitudes and reasons for medication nonadherence among three disparate groups of individuals with serious mental illness.

Authors:  Jennifer B Levin; Nasim Seifi; Kristin A Cassidy; Curtis Tatsuoka; Johnny Sams; Kouri K Akagi; Martha Sajatovic
Journal:  J Nerv Ment Dis       Date:  2014-11       Impact factor: 2.254

8.  Clinical Characteristics of Patients with Late Life Bipolar Disorder in the Community: Data from the NNDC Registry.

Authors:  Brent P Forester; Olu Ajilore; Cathie Spino; Susan W Lehmann
Journal:  Am J Geriatr Psychiatry       Date:  2015-01-15       Impact factor: 4.105

9.  Characteristics of bipolar disorder patients treated with immediate- and extended-release quetiapine in a real clinical setting: a longitudinal, cohort study of 1761 patients.

Authors:  Andreas Carlborg; Marcus Thuresson; Lena Ferntoft; Johan Bodegard
Journal:  Ther Adv Psychopharmacol       Date:  2015-02

10.  Use of automated medication adherence monitoring in bipolar disorder research: pitfalls, pragmatics, and possibilities.

Authors:  Jennifer B Levin; Johnny Sams; Curtis Tatsuoka; Kristin A Cassidy; Martha Sajatovic
Journal:  Ther Adv Psychopharmacol       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.